Literature DB >> 20510730

OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.

Naoto Ishii1, Takeshi Takahashi, Pejman Soroosh, Kazuo Sugamura.   

Abstract

T-cell activation is mediated not only by antigen stimulation through T-cell receptors but also by costimulatory signals through costimulatory molecules. Among several costimulatory molecules, the tumor necrosis factor (TNF) receptor family member OX40 plays a key role in the survival and homeostasis of effector and memory T cells. According to the conventional understanding of OX40 costimulation, an interaction between OX40 and OX40 ligand (OX40L) occurs when activated T cells bind to professional antigen-presenting cells (APCs). The T-cell functions, including cytokine production, expansion, and survival, are then enhanced by the OX40 costimulatory signals. Over the last half-decade, evidence has accumulated that OX40 signals are critical for controlling the function and differentiation of Foxp3(+) regulatory T cells, indicating a new aspect of OX40-mediated autoimmunity. Furthermore, the expression of OX40L by mast cells was shown to be important for controlling inflammation through regulatory T-cell function. Besides the essential role played by OX40 signaling in generating memory CD4 T cells, recent reports show that it also has a unique role in generating memory CD8 T cells. In addition, recent genome-wide association studies have identified single-nucleotide polymorphisms of the OX40L and OX40 genes that are related to cardiovascular diseases and SLE, providing direct evidence for the involvement of the OX40-OX40L interaction in human diseases. Here, we review recent progress on how the OX40-OX40L interaction regulates T-cell tolerance, peripheral T-cell homeostasis, and T-cell-mediated inflammatory diseases. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510730     DOI: 10.1016/S0065-2776(10)05003-0

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  51 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Lymphocyte mass cytometry identifies a CD3-CD4+ cell subset with a potential role in psoriasis.

Authors:  Ruru Guo; Ting Zhang; Xinyu Meng; Zhen Lin; Jinran Lin; Yu Gong; Xuesong Liu; Yuetian Yu; Guilin Zhao; Xianting Ding; Xiaoxiang Chen; Liangjing Lu
Journal:  JCI Insight       Date:  2019-03-21

Review 3.  Genetics of systemic sclerosis.

Authors:  Lara Bossini-Castillo; Elena López-Isac; Maureen D Mayes; Javier Martín
Journal:  Semin Immunopathol       Date:  2015-06-02       Impact factor: 9.623

4.  Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction.

Authors:  Yun Song; Emilio Margolles-Clark; Allison Bayer; Peter Buchwald
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

5.  Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.

Authors:  M-N Theodoraki; T K Hoffmann; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2018-03-12       Impact factor: 4.330

6.  The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.

Authors:  Jonathan Sitrin; Eric Suto; Arthur Wuster; Jeffrey Eastham-Anderson; Jeong M Kim; Cary D Austin; Wyne P Lee; Timothy W Behrens
Journal:  J Immunol       Date:  2017-07-10       Impact factor: 5.422

7.  TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Authors:  Viraga Haridas; Polidy Pean; Luke D Jasenosky; Yoann Madec; Didier Laureillard; Thim Sok; Sun Sath; Laurence Borand; Olivier Marcy; Sarin Chan; Erdyni Tsitsikov; Jean-François Delfraissy; François-Xavier Blanc; Anne E Goldfeld
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

8.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

9.  Naturally occurring immunoglobulin M (nIgM) autoantibodies prevent autoimmune diabetes and mitigate inflammation after transplantation.

Authors:  Preeti Chhabra; Kailo Schlegel; Mark D Okusa; Peter I Lobo; Kenneth L Brayman
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

10.  Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB.

Authors:  Yosuke Motai; Masahiko Takahashi; Takayuki Takachi; Masaya Higuchi; Toshifumi Hara; Mariko Mizuguchi; Yutaka Aoyagi; Shuji Terai; Yuetsu Tanaka; Masahiro Fujii
Journal:  Virus Genes       Date:  2016-01-06       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.